quote: OPENAI ACQUIRES DRUG DEVELOPMENT PLATFORM ORCHESTRA BIO https://x.com/IPONewsroom_/status/2112606383824900604 | OPENAI ACQUIRES DRUG DEVELOPMENT PLATFORM ORCHESTRA BIO The ChatGPT maker is pushing deeper into biotech Orchestra Bio helps biopharma teams coordinate drug development. On its platform, people and AI agents work together to track studies and flag problems before they cause delays. OpenAI is combining Orchestra's team and technology with Rosalind, its AI models and tools for life sciences research. The goal is to get new medicines to patients sooner. Right now it takes roughly 10 to 15 years on average to go from target discovery to approval in the US. OpenAI already works with Novo Nordisk $NVO and Moderna $MRNA on AI in drug research. It didn't disclose what it paid for Orchestra.